A multicenter phase II study assessed safety and efficacy of asunaprevir and daclatasvir in patients with chronic hepatitis C virus genotype 1 infection and end-stage renal disease requiring hemodialysis
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Jun 2017 Status changed from active, no longer recruiting to completed.
- 09 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2014 New trial record